P 2202

Drug Profile

P 2202

Alternative Names: P2202

Latest Information Update: 11 Jun 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Piramal Enterprises
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2013 Piramal Life Sciences completes a phase I pharmacokinetics trial (healthy volunteers) in India (CTRI2010-091-002992)
  • 03 Jun 2013 Piramal Healthcare terminates a phase II trial in Type 2 diabetes mellitus in Canada and India (NCT01674348)
  • 25 Feb 2013 Piramal Healthcare completes enrolment in its phase I trial in healthy volunteers in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top